ACM
IOVA icon

Aquatic Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Aquatic Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-46,955
Closed -$165K – 1485
2026
Q1 		$165K Buy
+46,955
New +$150K ﹤0.01% 1023
2024
Q4 		– Sell
-35,200
Closed -$331K – 1467
2024
Q3 		$331K Buy
+35,200
New +$333K 0.01% 729
2024
Q2 		– Sell
-21,900
Closed -$325K – 1408
2024
Q1 		$325K Buy
+21,900
New +$255K 0.01% 651
2023
Q2 		– Sell
-10,500
Closed -$64K – 1535
2023
Q1 		$64K Buy
+10,500
New +$72.4K ﹤0.01% 838
2022
Q4 		– Sell
-68,000
Closed -$651K – 1585
2022
Q3 		$651K Buy
68,000
+57,600
+554% +$664K 0.06% 349
2022
Q2 		$115K Buy
10,400
+9,900
+1,980% +$130K 0.04% 453
2022
Q1 		$8K Buy
+500
New +$7.73K 0.01% 725

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Aquatic Capital Management's IOVA Position: Q2 2026 in Review

Aquatic Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 46,955 shares — an estimated $165K sold.

Aquatic Capital Management first reported a position in IOVA in Q1 2022 and held it in 7 quarters. The position peaked at $651K in Q3 2022. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Aquatic Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 46,955 Iovance Biotherapeutics shares in Q2 2026, an estimated $165K.
  • Aquatic Capital Management first reported a position in Iovance Biotherapeutics in Q1 2022 and held it in 7 quarters.
  • Aquatic Capital Management's Iovance Biotherapeutics position peaked at $651K in Q3 2022.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.